

TRIMURTHI LIMITED

(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)
SCHEDULE III OF THE COMPANIES ACT 2013

STANDALONE UNAUDITED STATEMENT OF PROFIT AND LOSS FOR THE QUARTER ENDED JUNE, 2017.



TRIMURTHI

(Rs. In Lakhs)

PART-I

Particulars	Quarter Ended			Year Ended
	30/06/2017	31/03/2017	30/06/2016	31/03/2017
	Unaudited	Audited	Unaudited	Audited
I. Revenue From Operations				
Net Sales / Income from Operations	30.36	12.19	157.80	289.48
Other Income	22.64	17.64	10.06	75.89
Total Income(Net)	52.99	29.82	167.86	365.36
II. Other Income	-Nil-	-Nil-	-Nil-	-Nil-
III. Total Income	52.99	29.82	167.86	365.36
IV. Expenses				
a. Consumption of Raw Material	-Nil-	-Nil-	-Nil-	-Nil-
b. Purchase of Traded Goods/Shares	0.29	0.16	173.41	306.88
c. (Increase)/Decrease in stock in trade and work in Progress	21.92	12.36	(16.46)	(21.92)
d. Employee benefits expense	5.81	5.80	5.28	21.62
e. Rent	0.75	1.15	0.75	3.00
f. Finance Cost	0.00	0.00	-Nil-	0.00
g. Depreciation	3.69	3.58	2.89	12.29
h. Other Expenditure	5.36	7.62	7.46	23.08
Total	37.81	30.67	173.34	344.95
V. Profit/ (Loss) before Exceptional and Tax (III-IV)	15.18	(0.84)	(5.48)	20.42
VI. Exceptional Items	Nil	Nil	Nil	Nil
VII. Profit/ (Loss) before tax (V-VI)	15.18	(0.84)	(5.48)	20.42
VIII. Tax expense:				
(1) Current tax	4.37	(1.48)	(0.03)	5.33
(2) Deferred tax	(0.29)	0.90	(0.03)	(0.06)
IX. Net Profit/ (Loss) for the period from continuing operations (VII-VIII)	10.81	0.63	(5.45)	15.09
X. Profit/(loss) from discontinued operations	-Nil-	-Nil-	-Nil-	-Nil-
XI. Tax expenses of discontinued operations	-Nil-	-Nil-	-Nil-	-Nil-
XII. Profit/(loss) from Discontinued operations (after tax) (X-XI)	-Nil-	-Nil-	-Nil-	-Nil-
XIII. Profit/(loss) for the period (IX+XII)	10.81	0.63	(5.45)	15.09
XIV. Other Comprehensive Income				
A. (i) Items that will not be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-
B. (i) Items that will be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-
(ii) Income tax relating to items that will be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-
XV. Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	10.81	0.63	(5.45)	15.09
XVI. Earnings per equity share (for continuing operation):				
(1) Basic	0.13	0.01	(0.07)	0.19
(2) Diluted	0.13	0.01	(0.07)	0.19
XVII. Earnings per equity share (for discontinuing operation):				
(1) Basic	-Nil-	-Nil-	-Nil-	-Nil-
(2) Diluted	-Nil-	-Nil-	-Nil-	-Nil-
XVIII. Earnings per equity share (for discontinuing & continuing operation):				
(1) Basic	0.13	0.01	(0.07)	0.19
(2) Diluted	0.13	0.01	(0.07)	0.19



TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370

TRIMURTHI LIMITED
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)



TRIMURTHI
GROUP

STANDALONE UNAUDITED STATEMENT OF PROFIT AND LOSS FOR THE QUARTER ENDED JUNE, 2017.

PART-II

Particulars		Quarter Ended	
		30/06/2017	30/06/2016
		Audited	Audited
A. Particulars Of Share Holding			
1.	Public Share Holding		
	- Number of Shares	2900600	2849600
	- Percentage of shareholding	35.81%	35.18%
2.	Promoters and promoter group shareholding		
	a. Pledged / encumbered		
	- No of Equity Shares	-Nil-	-Nil-
	- Percentage of Shares (of the shareholding of promoter and promoter group)	-Nil-	-Nil-
	- Percentage of Shares (of the total share capital of the company)	-Nil-	-Nil-
	b. Non encumbered		
	- No of Equity Shares	5199400	5250400
	- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%
	- Percentage of Shares (of the total share capital of the company)	64.19%	64.82%

Particulars		3 Months Ended (30/06/2017)
B. Investor Complaints		
	Pending at the beginning of the quarter	-NIL-
	Received during the quarter	-NIL-
	Disposed during the quarter	-NIL-
	Remaining unsolved during the quarter	-NIL-

Segment Reporting

Particulars		Quarters ended			Period ended
		30/06/2017	31/03/2017	30/06/2016	31/03/2017
		Audited	Unaudited	Audited	Audited
1.	Segment Revenue				
	a. Pharma Business	0.00	0.00	0.00	0.00
	b. Financial Services	20.66	14.02	10.19	62.50
	c. Investments	0.00	4.99	(0.08)	13.38
	d. Trading in Shares	32.34	10.82	157.74	289.49
	Total	52.99	29.82	167.86	365.36
	Less: Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-
	Net Sales/ Income From Operations	52.99	29.82	167.86	365.36
2.	Segment Profits (Before tax & Interest From Each Segment)				
	a. Pharma Business		0.00	0.00	0.00
	b. Financial Services	15.63	14.83	2.05	37.02
	c. Investments	0.00	4.49	(0.13)	13.97
	d. Trading in Shares	(0.45)	(20.16)	(7.40)	(30.57)
	Total	15.18	(0.84)	(5.48)	20.42
	Less:				
	i. Interest	-Nil-	-Nil-	-Nil-	-Nil-
	ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-
	iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-
	Total Profit Before Tax	15.18	(0.84)	(5.48)	20.42
3.	Capital Employed				
	a. Pharma Business		0.00	1.36	0.00
	b. Financial Services	678.97	640.95	281.03	640.95
	c. Investments	184.34	184.34	572.43	184.34
	d. Trading in Shares	305.74	334.14	283.82	334.14
	Total	1169.06	1159.43	1138.64	1159.43

Notes:

- The above results have been taken on record by the board of directors of the company at their meeting held on 05-08-2017
- The financial results for the quarter ended 30-06-2017 have been reviewed by the statutory auditors in pursuance of listing agreement.
- In segment reporting common assets that are used interchangeable not allocated to the individual segment above.
- These results have been prepared in accordance with the companies (Indian Accounting standards) Rules 2015 (IND AS) prescribed under section 133 of the companies Act 2013 and other recognised accounting practises to the extent applicable. Effective from the 1st April 2017 the company has for the first time adopted IND AS.
- These results do not include IND AS compliant result for the immediate preceding quarter (31-03-2017)(Audited), Corresponding Quarter for Previous Year(30-06-2016)(Unaudited) and the previous year ended 31st March 2017(Audited) as the same is not mandatory as per the SEBT's Circular dated 5th July 2016.

